Bambusa Therapeutics, Inc. Form S-1/A — Oct 26, 2026
Bambusa Therapeutics filed Amendment No. 1 to its S-1 for a 9,375,000-share IPO priced at $15.00-$17.00 per share, seeking a Nasdaq Global Select Market listing under the symbol BBTX with BofA Securities, Evercore ISI, UBS and Cantor as underwriters. Estimated net proceeds are approximately $134.9 million at the $16.00 midpoint, with roughly $90 million earmarked for BBT001 and $40 million for BBT002, plus a 1,406,250-share underwriter option and a 3.5% reserved share program.
Key figures
- Net Loss
- $22.4M for six months ended June 30, 2026; $41.1M FY2025
- Cash Position
- $46.5M cash + $24.9M marketable securities as of June 30, 2026; ~$57.2M total as of September 30, 2026 (preliminary); $181.4M pro forma as adjusted cash
- Gross Proceeds
- 0
- Offering Price
- $15.00-$17.00 (assumed midpoint $16.00)
- Shares Offered
- 9375000
- Shares Outstanding
- 49,761,875 post-offering (51,168,125 with full greenshoe)
- Employees
- 30 full-time as of September 30, 2026
- Cash runway
- into late 2028 post-offering
- Stock split
- 1.54485-for-1 forward split effected October 23, 2026
- Greenshoe shares
- 1406250
- Accumulated deficit
- $77.2M as of June 30, 2026
- Net proceeds midpoint
- $134.9M ($155.8M with full greenshoe)
- Reserved share program
- 3.5%
- Gross private financings raised
- $136.1M
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.